To raise awareness and funding for this "forgotten" cancer.

The Hope Fund for Sarcoma Research is dedicated to supporting research on Soft Tissue Sarcomas, a group of rare but deadly cancers. The Hope Fund is currently supporting a two-year project led by Dina Lev, M.D., at the M.D. Anderson Cancer Center, as well as a high powered international collaboration led by Wei Zhang, Ph.D., also at the M.D. Anderson Cancer Center. The team of collaborators includes Jonathan Trent, M.D., Ph.D. and Raphael Pollock, M.D., Ph.D., Director of the Sarcoma Center, at the M.D. Anderson Cancer Center, as well as Jilong Yang, M.D., and Kexin Chen, M.D., Ph.D., Director of the Joint Tissue Banking Facility at the Tianjin Cancer Institute and Hospital. These projects focus on molecular and genetic analyses and identification of new biomarkers in Soft Tissue Sarcomas, in particular Malignant Peripheral Nerve Sheath Tumors (MPNST). Progress in these important areas may lead to new and better treatments for MPNST and other Soft Tissue Sarcomas. For more information, visit: www.hopefundcancerresearch.org.

1. There is a huge void when it comes to sarcomas. There is very little pertinent information and even less consensus about the proper treatment.

2. Rare sarcomas (by nature, less than 10,000 new cases per year) continue to be misdiagnosed and misunderstood.

3. We serve the need for “seed funding” in innovative research projects which may lead to the discovery of additional new therapies for a cure.

4. http://www.nfcr.org/HopeFundforSarcoma/tabid/161/Default.aspx